JPWO2023042887A5 - - Google Patents

Info

Publication number
JPWO2023042887A5
JPWO2023042887A5 JP2023548505A JP2023548505A JPWO2023042887A5 JP WO2023042887 A5 JPWO2023042887 A5 JP WO2023042887A5 JP 2023548505 A JP2023548505 A JP 2023548505A JP 2023548505 A JP2023548505 A JP 2023548505A JP WO2023042887 A5 JPWO2023042887 A5 JP WO2023042887A5
Authority
JP
Japan
Prior art keywords
overweight
pharmaceutical composition
subject
obesity
obese
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548505A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023042887A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/034601 external-priority patent/WO2023042887A1/ja
Publication of JPWO2023042887A1 publication Critical patent/JPWO2023042887A1/ja
Publication of JPWO2023042887A5 publication Critical patent/JPWO2023042887A5/ja
Pending legal-status Critical Current

Links

JP2023548505A 2021-09-15 2022-09-15 Pending JPWO2023042887A1 (https=)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021150271 2021-09-15
JP2022128640 2022-08-12
PCT/JP2022/034601 WO2023042887A1 (ja) 2021-09-15 2022-09-15 認知機能低下、または過体重もしくは肥満症を処置することに用いるための医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2023042887A1 JPWO2023042887A1 (https=) 2023-03-23
JPWO2023042887A5 true JPWO2023042887A5 (https=) 2025-10-02

Family

ID=85602988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548505A Pending JPWO2023042887A1 (https=) 2021-09-15 2022-09-15

Country Status (4)

Country Link
US (1) US20240398775A1 (https=)
EP (1) EP4403184A4 (https=)
JP (1) JPWO2023042887A1 (https=)
WO (1) WO2023042887A1 (https=)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2436261B2 (de) 1974-07-27 1976-11-25 Bayer Ag, 5090 Leverkusen Elektrochemische gasdetektoren
DK146787A (da) 1987-03-23 1988-09-24 Ferrosan Heterocykliske forbindelser, deres fremstilling og anvendelse
HU221425B (en) 1990-11-06 2002-10-28 Yamanouchi Pharma Co Ltd Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
US5639751A (en) 1990-12-21 1997-06-17 Cyogyszerkutato Intezet Kft N-acyl-2,3-benzodiazepine derivatives for treating acute and chronic neurodegenerative disorders
FR2711993B1 (fr) 1993-11-05 1995-12-01 Rhone Poulenc Rorer Sa Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
EP0743945B1 (en) 1994-02-11 2002-03-06 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
DK0784054T3 (da) 1994-09-27 2002-03-25 Yamanouchi Pharma Co Ltd 1,2,3,4-tetrahydroquinoxalinderivater og deres anvendelse som glutamatreceptorantagonister
WO1996015099A1 (en) 1994-11-09 1996-05-23 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
AUPN842196A0 (en) 1996-03-05 1996-03-28 Fujisawa Pharmaceutical Co., Ltd. New compound
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
HUP9701325A1 (hu) 1997-07-31 2000-08-28 Gyógyszerkutató Intézet Kft. Új 2,3-benzodiazepin-származékok
UA67749C2 (uk) 1997-08-12 2004-07-15 Егіш Дьйодьсердьяр Рт. Похідна 8-заміщеного-9н-1,3-діоксол/4,5-h//2,3/бензодіазепіну з властивостями амра/каїнатного антагоніста, спосіб одержання похідних, фармацевтична композиція (варіанти), спосіб її одержання та спосіб лікування
ES2320973T3 (es) 2000-06-12 2009-06-01 EISAI R&D MANAGEMENT CO., LTD. Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos.
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
EP1491211A4 (en) 2002-03-29 2010-01-13 Astellas Pharma Inc DRUG AGAINST GLIOBLASTOMA
AU2006232517A1 (en) * 2005-04-04 2006-10-12 Eisai R&D Management Co., Ltd. Dihydropyridine compounds and compositions for headaches
WO2008111590A2 (en) * 2007-03-05 2008-09-18 Eisai R & D Management Co., Ltd. Ampa and nmda receptor antagonists for neurodegenerative diseases

Similar Documents

Publication Publication Date Title
Mirza et al. Frequent periodic leg movement during sleep is associated with left ventricular hypertrophy and adverse cardiovascular outcomes
Hinojosa et al. Resolution of systemic hypertension after laparoscopic gastric bypass
Colagiuri Diabesity: therapeutic options
JP2013536857A5 (https=)
JP2013539470A5 (https=)
RU2010120808A (ru) Производное амина, обладающее активностью антагониста npy y5 рецептора, и его применение
Brashier et al. Obesity and asthma: physiological perspective
JP2020530837A5 (https=)
JPWO2023042887A5 (https=)
Du et al. A comparative study of the metabolic effects of LSG and LRYGB in Chinese diabetes patients with BMI< 35 kg/m2
JP2013507442A5 (https=)
JP2013514078A (ja) 中空麺の製造方法
JP2013536859A5 (https=)
JP2013502420A5 (https=)
Ballem et al. Gastrointestinal symptom improvement after Roux-en-Y gastric bypass: long-term analysis
Choi et al. Effect of combination therapy of oral famotidine with mosapride on intragastric pH and gastric emptying in rats
CN102892760A (zh) 非醇性脂肪性肝炎的预防和/或治疗剂
CN1726794A (zh) 一种荞麦茶及其制备方法
Helvaci et al. Physical inactivity or an excessive eating habit
WO2010009619A1 (zh) 用于治疗高血压和代谢综合症的药物组合物及其应用
CN116018141A (zh) 一种含吲哚类衍生物的盐、晶型及其制备方法和应用
Sun et al. Effect of sleeve gastrectomy on gastroesophageal reflux in patients with metabolic syndrome
Yip et al. central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti‐viral therapy.
Dineros et al. Obesity surgery in the Philippines: experience in a private tertiary care hospital for years 2002 to 2004
Song et al. Progress of clinical research on treating obese type 2 diabetes based on spleen deficiency and phlegm dampness